These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12614300)

  • 1. Review article: gastric acidity--comparison of esomeprazole with other proton pump inhibitors.
    Hatlebakk JG
    Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():10-5; discussion 16-7. PubMed ID: 12614300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
    Johnson DA; Stacy T; Ryan M; Wootton T; Willis J; Hornbuckle K; Brooks W; Doviak M
    Aliment Pharmacol Ther; 2005 Jul; 22(2):129-34. PubMed ID: 16011671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
    Katz PO; Hatlebakk JG; Castell DO
    Aliment Pharmacol Ther; 2000 Jun; 14(6):709-14. PubMed ID: 10848653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: is stringent control of gastric pH useful and practical in GERD?
    Kahrilas PJ
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():89-94; discussion 95-6. PubMed ID: 15456470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R
    Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
    Frazzoni M; Manno M; De Micheli E; Savarino V
    Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
    Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
    Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
    Katz PO; Anderson C; Khoury R; Castell DO
    Aliment Pharmacol Ther; 1998 Dec; 12(12):1231-4. PubMed ID: 9882031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study.
    Wilder-Smith C; Backlund A; Eckerwall G; Lind T; Fjellman M; Röhss K
    Clin Drug Investig; 2008; 28(6):333-43. PubMed ID: 18479175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
    Nzeako UC; Murray JA
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1309-16. PubMed ID: 12144581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.
    Gardner JD; Sloan S; Miner PB; Robinson M
    Aliment Pharmacol Ther; 2003 Apr; 17(7):955-64. PubMed ID: 12656698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults.
    Pisegna JR; Sostek MB; Monyak JT; Miner PB
    Aliment Pharmacol Ther; 2008 Mar; 27(6):483-90. PubMed ID: 18162083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
    Goldstein JL; Miner PB; Schlesinger PK; Liu S; Silberg DG
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1189-96. PubMed ID: 16611280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.
    Morgan D; Pandolfino J; Katz PO; Goldstein JL; Barker PN; Illueca M
    Aliment Pharmacol Ther; 2010 Jul; 32(2):200-8. PubMed ID: 20456300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
    Robinson M
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():30-7. PubMed ID: 15496216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
    Wilder-Smith CH; Röhss K; Nilsson-Pieschl C; Junghard O; Nyman L
    Digestion; 2003; 68(4):184-8. PubMed ID: 14691345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.